What is MannKind?
MannKind Corporation is dedicated to the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases within the United States. Its product portfolio includes Afrezza Inhalation Powder, an inhaled insulin designed to enhance glycemic control in adult patients with diabetes, and the V-Go wearable insulin delivery device, which facilitates continuous subcutaneous insulin infusion. Additionally, the company offers Tyvaso DPI, a treatment for pulmonary arterial hypertension and pulmonary hypertension. The company's focus on these critical health areas underscores its commitment to addressing unmet medical needs.
How much funding has MannKind raised?
MannKind has raised a total of $1.7B across 13 funding rounds:
Corporate Investment
$150M
Stock Offering
$36.2M
Stock Offering
$47.5M
Stock Offering
$61M
Stock Offering
$28M
Debt
$2M
Stock/Share Issuance
$500M
Corporate Investment (2014): $150M led by Sanofi
Stock Issuance/Offering (2015): $36.2M, investors not publicly disclosed
Stock Issuance/Offering (2016): $47.5M, investors not publicly disclosed
Stock Issuance/Offering (2017): $61M, investors not publicly disclosed
Stock Issuance/Offering (2018): $28M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Stock/Share Issuance (2025): $500M, investors not publicly disclosed
Key Investors in MannKind
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation. The company focuses on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care. Guided by research and patient needs, it works with healthcare partners worldwide to advance sustainable and responsible healthcare solutions.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research. Deerfield also engages in philanthropic efforts through its New York City-based not-for-profit, Cure, which fosters innovative healthcare initiatives. Their collaborative approach connects people, capital, ideas, and technology to build and enhance healthcare solutions.
PPP
Public-Private Partnership
What's next for MannKind?
With the recent injection of $500M in a major strategic investment, MannKind is well-positioned to advance its research and development initiatives. This capital is expected to fuel the progression of its therapeutic candidates through clinical trials and toward commercialization. The company's strategic focus on diabetes and pulmonary diseases, coupled with its innovative delivery systems, suggests a trajectory aimed at expanding its market presence and impact. Future endeavors will likely involve further clinical validation, potential partnerships, and broader market access for its existing and pipeline products, reinforcing its role in the biopharmaceutical landscape.
See full MannKind company page
